SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
  • 2
    Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294-1305.
  • 3
    Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009; 49( suppl): S129-S137.
  • 4
    Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356.
  • 5
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
  • 6
    Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003; 3: 250-258.
  • 7
    Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700.
  • 8
    Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308.
  • 9
    Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004; 24( suppl 1): 55-62.
  • 10
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
  • 11
    Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-496.
  • 12
    Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-525.
  • 13
    McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512-519.
  • 14
    Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433.
  • 15
    Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910.
  • 16
    Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Böker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
  • 17
    Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002; 4: 137-143.
  • 18
    Steinmüller T, Seehofer D, Rayes N, Müller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535.
  • 19
    Park SJ, Paik SW, Choi MS, Lee JH, Koh KC, Kim SJ, et al. Is lamivudine with 1-week HBIg as effective as long-term high-dose HBIg in HBV prophylaxis after liver transplantation? Transplant Proc 2002; 34: 1252-1254.
  • 20
    Sousa JM, Pareja F, Serrano J, Gómez MA, García I, Tamayo MJ, et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transplant Proc 2003; 35: 723-724.
  • 21
    Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003; 3: 999-1002.
  • 22
    Ben-Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R. Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients. Transplant Proc 2003; 35: 609-611.
  • 23
    Zhu JP, Zhang TL, Li L, Yuan J, Song SB, Xiu DR, et al. Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2003; 2: 500-503.
  • 24
    Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 2004; 36: 535-538.
  • 25
    Wang ZX, Fu ZR, Ding GS, Zhang JJ, Fu H, Zhang M, Zhang CY. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Transplant Proc 2004; 36: 2315-2317.
  • 26
    Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813.
  • 27
    Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-538.
  • 28
    Caccamo L, Romeo R, Rossi G, Maggioni M, Radice F, Lunghi G, et al. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Transpl Int 2005; 18: 186-192.
  • 29
    Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258.
  • 30
    Karademir S, Astarcioğlu H, Akarsu M, Ozkardesler S, Ozzeybek D, Sayiner A, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006; 38: 579-583.
  • 31
    Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20: 206-210.
  • 32
    Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al.; for Adefovir Dipivoxil Study, 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360.
  • 33
    Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW; for Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
  • 34
    Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant 2007; 21: 510-517.
  • 35
    Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007; 13: 451-458.
  • 36
    Yoshida H, Kato T, Levi DM, Regev A, Madariaga JR, Nishida S, et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007; 21: 166-171.
  • 37
    Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-381.
  • 38
    Neff GW, Kemmer N, Kaiser TE, Zacharias VC, Alonzo M, Thomas M, Buell J. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52: 2497-2500.
  • 39
    Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc 2007; 39: 3276-3280.
  • 40
    Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130- 2134.
  • 41
    Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650-654.
  • 42
    Takaki A, Yagi T, Iwasaki Y, Sadamori H, Matsukawa H, Matsuda H, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007; 83: 231-233.
  • 43
    Yang Y, Zhang Q, Cai CJ, Lu MQ, Li X, Jiang N, et al. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. Chin Med J (Engl) 2007; 120: 1400-1403.
  • 44
    Freshwater DA, Dudley T, Cane P, Mutimer DJ. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008; 85: 1105-1111.
  • 45
    Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008; 14: 435-442.
  • 46
    Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, et al. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008; 28: 72-78.
  • 47
    Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2008; 7: 357-361.
  • 48
    Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, et al. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008; 40: 1961-1964.
  • 49
    Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
  • 50
    Ahn S, Dodson SF, Cohen SM. Oral antiviral therapy without long term maintenance hepatitis B immunoglobulin to prevent hepatitis B recurrence in liver transplant patients [abstract]. J Hepatol 2008; 48( suppl 2): S73-S74.
  • 51
    Giusto M, Gentilli F, Loria I, Grieco S, Rossi M, Novelli G, et al. Combined therapy with low dose hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) in patients transplanted for HBV chronic liver disease: long term efficacy and costs [abstract]. J Hepatol 2008; 48( suppl 2): S84.
  • 52
    Woo HY, Choi JY, Jang JW, You CR, Bae SH, Yoon SK, et al. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 2008; 80: 1891-1899.
  • 53
    Beckebaum S, Sotiropoulos GC, Klein CG, Broelsch CE, Saner F, Paul A, et al. Predictive factors of outcome in patients transplanted for hepatitis B. Transplantation 2009; 87: 872-881.
  • 54
    Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10: 1861-1869.
  • 55
    Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS Jr, et al.; for NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823-1833.
  • 56
    Karasu Z, Ozacar T, Akyildiz M, Demirbas T, Arikan C, Kobat A, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 921-927.
  • 57
    Seehofer D, Rayes N, Steinmüller T, Müller AR, Settmacher U, Neuhaus R, et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001; 7: 976-982.
  • 58
    Chu CJ, Fontana RJ, Moore C, Armstrong DR, Punch JD, Su GL, et al. Outcome of liver transplantation for hepatitis B: report of a single center's experience. Liver Transpl 2001; 7: 724-731.
  • 59
    Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 611-619.
  • 60
    Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
  • 61
    Neff GW, O'Brien CB, Nery J, Shire N, Montalbano M, Ruiz P, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-1378.
  • 62
    Lee PH, Hu RH, Tsai MK, Ho MC, Lai HS, Lai MY, Yang PM. Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transplant Proc 2000; 32: 2245-2247.
  • 63
    Jiao ZY, Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc 2007; 39: 1533-1536.
  • 64
    Chun J, Kim W, Kim BG, Lee KL, Suh KS, Yi NJ, et al. High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant 2010; 10: 1649-1659.
  • 65
    Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10: 321-327.
  • 66
    Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009; 22: 387-394.
  • 67
    Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49( suppl): S174-S184.